The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

Steffen Jørgensen, Isabella Worlewenut Paulsen, Jakob Werner Hansen, Dorte Tholstrup, Christoffer Hother, Erik Sørensen, Mikkel Steen Petersen, Kaspar Rene nielsen, Klaus Rostgaard, Margit Anita Hørup Larsen, Peter de Nully Brown, Elisabeth Ralfkiær, Keld Mikkelsen Homburg, Henrik Hjalgrim, Christian Erikstrup, Henrik Ullum, Jesper Thorvald Troelsen, Kirsten Grønbæk, Ole Birger Pedersen*

*Corresponding author

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.
TidsskriftScientific Reports
Udgave nummer10
StatusUdgivet - 2020

Citer dette